P&U Aromasin
Executive Summary
Pharmacia & Upjohn has not conducted head to head trials of cancer therapy Aromasin and Novartis' Femara and Zeneca's Arimidex. At a March presentation to analysts, P&U compared Phase III results of the drugs from different trials and "cannot make any definitive conclusions about the efficacy of Aromasin versus the other two drugs based on indirect comparisons," the company says (1"The Pink Sheet" May 31, p. 29)